Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 2/20 | 0.64 |
| ▸ | RAF1 | P04049 | 2/20 | 0.59 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.59 |
| ▸ | PLK4 | O00444 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13081136 | 1.00 | MAPT (0.70) | MAPTMAPK1HTTGSK3BTGM2 | |
| SCHEMBL6857818 | 1.00 | MAPT (0.70) | MAPTMAPK1HTTGSK3BTGM2 | |
| SCHEMBL13080521 | 0.85 | LRRK2 (0.71) | MAPTMAPK1HTTGSK3BTGM2 | |
| SCHEMBL5365953 | 0.85 | MAPT (0.70) | MAPTMAPK1HTTGSK3BTGM2 | |
| SCHEMBL27613119 | 0.85 | LRRK2 (0.71) | MAPTMAPK1HTTGSK3BTGM2 | |
| SCHEMBL5727968 | 0.84 | MEN1 (0.66) | TGM2PLK4MEN1KMT2AMAP1LC3B | |
| SCHEMBL5727972 | 0.84 | MEN1 (0.66) | TGM2PLK4MEN1KMT2AMAP1LC3B | |
| SCHEMBL6835454 | 0.84 | MEN1 (0.73) | PLK4MEN1KMT2AMAP1LC3BRPS6KA3 | |
| SCHEMBL6857929 | 0.84 | MEN1 (0.73) | PLK4MEN1KMT2AMAP1LC3BRPS6KA3 | |
| SCHEMBL5727967 | 0.82 | MAPT (1.00) | MAPTMAPK1HTTGSK3BTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | MAPT 3336/4885MAPK1 40/4885HTT 4817/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | MAPT 3336/4885MAPK1 40/4885HTT 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.